Cohance Lifesciences' Pashamylaram Facility Gets USFDA EIR With VAI Status
Written By : Parthika Patel
Hyderabad: Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) has announced that the United States Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR) for its manufacturing facility located at Pashamylaram, Hyderabad.
In a regulatory disclosure,the company stated that the USFDA has classified the inspection outcome as Voluntary Action Indicated (VAI). The inspection was conducted at the facility bearing FEI No. 1000623515.
The company’s latest update follows its earlier communication dated August 5,2026,regarding the USFDA inspection of the Pashamylaram manufacturing facility.
With the issuance of the Establishment Inspection Report, the USFDA inspection has been officially concluded.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.